Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as CBA120, allows detection of a specific microorganism, such as E. coli O157:H7, and an indicator signal may be amplified to optimize assay sensitivity.

Bacteriophage against Geobacillus are provided, and methods of making and using the bacteriophage also are provided.

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

The present invention provides a virulent Pseudomonas fluorescens (P. fluorescens) phage ΦPf1901, and a phage ΦPf1901 preparation and an application thereof, and relates to the technical field of phage. The virulent P. fluorescens phage ΦPf1901 has an accession number of CCTCC M2019447. The virulent phage ΦPf1901 has a titer of (1.4-3)×10.sup.10 PFU/mL. The virulent phage ΦPf1901 has an optimal multiplicity of infection (MOI) value of 0.0001. The virulent P. fluorescens phage ΦPf1901 provided by the present invention exhibits very high specificity and lytic ability to P. fluorescens, which can be used to control P. fluorescens, with strong lytic and scavenging effects on a host.

The present invention relates, in part, to engineered viruses (e.g., engineered phages), phage cocktails, and methods of producing and/or identifying viruses for targeting pathogenic bacteria.

Bacteriophage are provided, and methods of making and using the bacteriophage also are provided.

In alternative embodiments, provided are products of manufacture and kits, and methods, to enrich for and/or isolate microbes such as viruses and/or phages capable of targeting, e.g., binding to, targeting, and/or killing or otherwise making non-viable or non-pathogenic, specific or desired microbes such as bacteria. In alternative embodiments, provided are products of manufacture comprising: a virus and/or a phage (a bacteriophage). In alternative embodiments, provided are products of manufacture and kits containing a virus and/or a phage (a bacteriophage) enriched for, selected for or isolated by a method as provided herein, or a microbe containing a virus and/or a phage (a bacteriophage) enriched, selected for and/or isolated by a method as provided herein.

Bacteriophage compositions and therapeutic uses thereof. In particular, compositions of lytic bacteriophages that are capable of lysing Propionibacterium acnes (P. acnes) bacterial strains associated with acne and biofilms, thereby treating or preventing acne and biofilms.

Disclosed herein is a targeted tumour-infiltrating bacteriophage. The bacteriophage is engineered to present an epidermal growth factor receptor (EGFR)-binding moiety on the bacteriophage cell surface. The EGFR-binding moiety is capable of binding the extracellular domain of the EGFR. Also disclosed are compositions, kits, methods and uses thereof. Also disclosed is a method of treating a tumour in a subject in need thereof, the method comprising: administering to the subject a composition comprising a plurality of bacteriophage engineered to present an epidermal growth factor receptor (EGFR)-binding moiety on the bacteriophage cell surface in a dose effective to treat the tumour, wherein the tumour is an EGFR-positive tumour and the EGFR-binding moiety is capable of binding an EGFR extracellular domain.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.